Publications by authors named "Giacome Boccuzzi"
Article Synopsis
- The PARIS score is used to assess the combined risk of ischemic and hemorrhagic events in patients with ischemic heart disease undergoing treatment with dual antiplatelet therapy (DAPT) after coronary stenting, particularly for those with acute coronary syndrome (ACS).
- A study involving 4,310 ACS patients treated with ticagrelor or prasugrel in Europe found that the PARIS scores can indicate the likelihood of ischemic and bleeding events, although the predictive accuracy (discrimination) was only modest.
- The study concluded that the PARIS model is useful for evaluating the balance between ischemic and hemorrhagic risks in ACS patients on DAPT, helping in risk assessment and management decisions.
Introduction And Objectives: There is little evidence on rates of stent thrombosis (ST) in patients receiving dual antiplatelet therapy (DAPT) with ticagrelor or prasugrel. The aim of this study was to analyze the incidence and predictors of ST after an acute coronary syndrome among patients receiving DAPT with ticagrelor vs prasugrel.
Methods: We used data from the RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction), analyzing a total of 4123 acute coronary syndrome patients discharged with DAPT with ticagrelor or prasugrel in 11 centers in 6 European countries.